[Form 4] Cigna Group Insider Trading Activity

Rhea-AI Filing Summary

Brian C. Evanko, President and Chief Operating Officer, reported option exercises and open-market sales of Common Stock of Cigna Group (CI) under a Rule 10b5-1 plan. On 10/03/2025 he exercised 5,368 employee stock options at an exercise price of $139.22 and sold 5,368 shares at a reported price of $300. On 10/06/2025 he exercised an additional 901 options at $139.22. The filing shows beneficial ownership following the transactions of 52,083 shares (direct) plus 904.1848 shares held indirectly in the company 401(k).

The transactions were effected under a 10b5-1 trading plan adopted on 05/07/2025. The option grants referenced were originally issued on 03/01/2016 with vesting in three equal annual installments; the options expire on 03/01/2026 as stated.

Insights

Compensation & Insider Transactions Analyst

Insider exercised options and executed plan-tied sales; holdings remained meaningful.

The reporting shows an exercise of $139.22-priced employee stock options and simultaneous sales on 10/03/2025 and a further exercise on 10/06/2025. The use of a Rule 10b5-1 trading plan adopted on 05/07/2025 indicates pre‑planned timing rather than ad hoc trades.

Key dependencies include option expiration on 03/01/2026 and continued vesting history from 03/01/2016. Watch near-term changes in direct holdings reported in subsequent Form 4 filings within the next weeks for additional plan activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evanko Brian C

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CT 06002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	10/03/2025		M(1)		5,368	A	$139.22	56,550	D
Common Stock, $.01 Par Value	10/03/2025		S(1)		5,368	D	$300	51,182	D
Common Stock, $.01 Par Value	10/06/2025		M(1)		901	A	$139.22	52,083	D
Common Stock, $.01 Par Value								904.1848(2)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$139.22	10/03/2025		M(1)			5,368	03/01/2017(3)	03/01/2026	Common Stock, $0.01 Par Value	5,368	$0	901	D
Employee Stock Option (Right to Buy)	$139.22	10/06/2025		M(1)			901	03/01/2017(3)	03/01/2026	Common Stock, $0.01 Par Value	901	$0	0	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025.

2. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

3. This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

Remarks:

President and Chief Operating Officer

	Tyler Gratton, attorney-in-fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.